{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T11:00:38Z","timestamp":1769079638963,"version":"3.49.0"},"reference-count":34,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T00:00:00Z","timestamp":1745539200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background: Daratumumab-based regimens represent the gold-standard therapy for newly diagnosed AL amyloidosis patients. However, there are few studies about the efficacy of this treatment in real life. Methods: This study included 99 patients: 27 (27.3%) received daratumumab and proteasome inhibitor-based schemes, 46 (46.4%) were treated with proteasome inhibitors and\/or immunomodulator-based regimens, and 26 (26.3%) were treated with chemotherapy. Results: Patients receiving daratumumab and proteasome inhibitor-based regimens achieved higher rates of partial haematological responses or better (100.0% vs. 78.3% vs. 58.3%; p = 0.009 and p &lt; 0.001) and complete responses (74.1% vs. 37.0% vs. 12.5%; p = 0.003 and p &lt; 0.001) than the proteasome inhibitors and\/or immunomodulators and chemotherapy groups, respectively. Daratumumab and proteasome inhibitor-based schemes resulted in a shorter time to haematological response (1 month to partial response or better and 4 months to complete response). Moreover, in the group treated with daratumumab and proteasome inhibitor-based regimens, there was a trend of obtaining better and faster organ responses. The benefit of daratumumab and proteasome inhibitor-based regimens was that they resulted in an improvement in progression-free survival (not reached) compared to the proteasome inhibitor and chemotherapy groups (18 months; p = 0.022 and 6 months; p = 0.002). In addition, the clinical benefit was consistent in patients with Mayo Clinic stages III\u2013IV. Conclusions: This study supports the efficacy and superiority of adding daratumumab to the frontline treatment over proteasome inhibitor-based regimens and chemotherapy in AL amyloidosis, including in advanced cardiac disease.<\/jats:p>","DOI":"10.3390\/cancers17091440","type":"journal-article","created":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T06:10:13Z","timestamp":1745561413000},"page":"1440","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Impact of the Addition of Daratumumab to the Frontline Treatment of Patients with Immunoglobulin Light-Chain Amyloidosis: A Single-Centre Experience"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0981-4882","authenticated-orcid":false,"given":"Elena","family":"Alejo","sequence":"first","affiliation":[{"name":"Hematology Department, University Hospital of Salamanca, Cancer Research Center-IBMCC (USAL-CSIC), Instituto de Investigaci\u00f3n Biom\u00e9dica de Salamanca (IBSAL), CIBERONC, 37007 Salamanca, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Agull\u00f3","sequence":"additional","affiliation":[{"name":"Biochemestry Department, University Hospital of Salamanca, Instituto de Investigaci\u00f3n Biom\u00e9dica de Salamanca (IBSAL), 37007 Salamanca, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-1491-5358","authenticated-orcid":false,"given":"Borja","family":"Puertas","sequence":"additional","affiliation":[{"name":"Hematology Department, University Hospital of Salamanca, Cancer Research Center-IBMCC (USAL-CSIC), Instituto de Investigaci\u00f3n Biom\u00e9dica de Salamanca (IBSAL), CIBERONC, 37007 Salamanca, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roc\u00edo","family":"Eiros","sequence":"additional","affiliation":[{"name":"Cardiology Department, University Hospital of Salamanca, Instituto de Investigaci\u00f3n Biom\u00e9dica de Salamanca (IBSAL), 37007 Salamanca, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beatriz","family":"Rey-B\u00faa","sequence":"additional","affiliation":[{"name":"Hematology Department, University Hospital of Salamanca, Cancer Research Center-IBMCC (USAL-CSIC), Instituto de Investigaci\u00f3n Biom\u00e9dica de Salamanca (IBSAL), CIBERONC, 37007 Salamanca, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen","family":"Barn\u00e9s","sequence":"additional","affiliation":[{"name":"Nephrology Department, University Hospital of Salamanca, 37007 Salamanca, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8544-6201","authenticated-orcid":false,"given":"Marta","family":"Rodr\u00edguez-Gonz\u00e1lez","sequence":"additional","affiliation":[{"name":"Pathology Department, University Hospital of Salamanca, 37007 Salamanca, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luc\u00eda","family":"L\u00f3pez-Corral","sequence":"additional","affiliation":[{"name":"Hematology Department, University Hospital of Salamanca, Cancer Research Center-IBMCC (USAL-CSIC), Instituto de Investigaci\u00f3n Biom\u00e9dica de Salamanca (IBSAL), CIBERONC, 37007 Salamanca, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c1ngel","family":"Santos-Briz","sequence":"additional","affiliation":[{"name":"Pathology Department, University Hospital of Salamanca, 37007 Salamanca, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4501-9066","authenticated-orcid":false,"given":"Fernando","family":"Escalante","sequence":"additional","affiliation":[{"name":"Hematology Department, University Hospital of Leon, 24008 Le\u00f3n, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda-Luisa","family":"P\u00e9rez-Garc\u00eda","sequence":"additional","affiliation":[{"name":"Internal Medicine Department, University Hospital of Salamanca, 37007 Salamanca, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Jim\u00e9nez-Cabrera","sequence":"additional","affiliation":[{"name":"Pharmacy Department, University Hospital of Salamanca, 37007 Salamanca, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5834-9510","authenticated-orcid":false,"given":"Norma C.","family":"Guti\u00e9rrez","sequence":"additional","affiliation":[{"name":"Hematology Department, University Hospital of Salamanca, Cancer Research Center-IBMCC (USAL-CSIC), Instituto de Investigaci\u00f3n Biom\u00e9dica de Salamanca (IBSAL), CIBERONC, 37007 Salamanca, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noemi","family":"Puig","sequence":"additional","affiliation":[{"name":"Hematology Department, University Hospital of Salamanca, Cancer Research Center-IBMCC (USAL-CSIC), Instituto de Investigaci\u00f3n Biom\u00e9dica de Salamanca (IBSAL), CIBERONC, 37007 Salamanca, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2390-1218","authenticated-orcid":false,"given":"Mar\u00eda-Victoria","family":"Mateos","sequence":"additional","affiliation":[{"name":"Hematology Department, University Hospital of Salamanca, Cancer Research Center-IBMCC (USAL-CSIC), Instituto de Investigaci\u00f3n Biom\u00e9dica de Salamanca (IBSAL), CIBERONC, 37007 Salamanca, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5493-6707","authenticated-orcid":false,"given":"Ver\u00f3nica","family":"Gonz\u00e1lez-Calle","sequence":"additional","affiliation":[{"name":"Hematology Department, University Hospital of Salamanca, Cancer Research Center-IBMCC (USAL-CSIC), Instituto de Investigaci\u00f3n Biom\u00e9dica de Salamanca (IBSAL), CIBERONC, 37007 Salamanca, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,4,25]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41572-018-0034-3","article-title":"Systemic Immunoglobulin Light Chain Amyloidosis","volume":"4","author":"Merlini","year":"2018","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Sarubbi, C., Abowali, H., Varga, C., and Landau, H. (2024). Treatment of AL Amyloidosis in the Era of Novel Immune and Cellular Therapies. Front. Oncol., 14.","DOI":"10.3389\/fonc.2024.1425521"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Puertas, B., Gonz\u00e1lez-Calle, V., Sobejano-Fuertes, E., Escalante, F., Queiz\u00e1n, J.A., B\u00e1rez, A., Labrador, J., Alonso-Alonso, J.M., Garc\u00eda De Coca, A., and Cantalapiedra, A. (2023). Novel Agents as Main Drivers for Continued Improvement in Survival in Multiple Myeloma. Cancers, 15.","DOI":"10.3390\/cancers15051558"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1182\/blood.V52.4.818.818","article-title":"Primary Systemic Amyloidosis: Comparison of Melphalan and Prednisone versus Placebo","volume":"52","author":"Kyle","year":"1978","journal-title":"Blood"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1111\/bjh.16143","article-title":"A 24-year Experience of Autologous Stem Cell Transplantation for Light Chain Amyloidosis Patients in the United Kingdom","volume":"187","author":"Sharpley","year":"2019","journal-title":"Br. J. Haematol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1002\/ajh.25566","article-title":"Fifteen Year Overall Survival Rates after Autologous Stem Cell Transplantation for AL Amyloidosis","volume":"94","author":"Sidana","year":"2019","journal-title":"Am. J. Hematol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1182\/blood-2015-01-620302","article-title":"A European Collaborative Study of Cyclophosphamide, Bortezomib, and Dexamethasone in Upfront Treatment of Systemic AL Amyloidosis","volume":"126","author":"Palladini","year":"2015","journal-title":"Blood"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1182\/blood.2019000834","article-title":"A Prospective Observational Study of 915 Patients with Systemic AL Amyloidosis Treated with Upfront Bortezomib","volume":"134","author":"Manwani","year":"2019","journal-title":"Blood"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1056\/NEJMoa2028631","article-title":"Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis","volume":"385","author":"Kastritis","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1182\/blood-2021-146820","article-title":"Subcutaneous Daratumumab with Bortezomib, Cyclophosphamide, and Dexamethasone in Patients with Newly Diagnosed Light Chain (AL) Amyloidosis: 18-Month Analysis of the Phase 3 ANDROMEDA Study","volume":"138","author":"Comenzo","year":"2021","journal-title":"Blood"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Sammartano, V., Antonioli, E., Buda, G., Ciofini, S., Candi, V., Pengue, L., Del Giudice, M., Attucci, I., Bacchiarri, F., and Occhini, U. (2022). Daratumumab in AL Amyloidosis: A Real-Life Experience of the \u201cRTM\u201d (Regional Tuscan Myeloma Network). J. Pers. Med., 12.","DOI":"10.3390\/jpm12030484"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e3289","DOI":"10.1002\/hon.3289","article-title":"A Real-life Study of Daratumumab Combinations in Newly Diagnosed Patients with Light Chain (AL) Amyloidosis","volume":"42","author":"Bellofiore","year":"2024","journal-title":"Hematol. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.3324\/haematol.2011.056176","article-title":"Report from the European Myeloma Network on Interphase FISH in Multiple Myeloma and Related Disorders","volume":"97","author":"Ross","year":"2012","journal-title":"Haematologica"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1200\/JCO.2011.38.5724","article-title":"Revised Prognostic Staging System for Light Chain Amyloidosis Incorporating Cardiac Biomarkers and Serum Free Light Chain Measurements","volume":"30","author":"Kumar","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"4541","DOI":"10.1200\/JCO.2011.37.7614","article-title":"New Criteria for Response to Treatment in Immunoglobulin Light Chain Amyloidosis Based on Free Light Chain Measurement and Cardiac Biomarkers: Impact on Survival Outcomes","volume":"30","author":"Palladini","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1038\/leu.2017.29","article-title":"Next Generation Flow for Highly Sensitive and Standardized Detection of Minimal Residual Disease in Multiple Myeloma","volume":"31","author":"Paiva","year":"2017","journal-title":"Leukemia"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1200\/JCO.22.00643","article-title":"Graded Cardiac Response Criteria for Patients With Systemic Light Chain Amyloidosis","volume":"41","author":"Muchtar","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2721","DOI":"10.1182\/blood-2021-149594","article-title":"Graded Renal Response Criteria for Light Chain (AL) Amyloidosis","volume":"138","author":"Muchtar","year":"2021","journal-title":"Blood"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/ejh.13679","article-title":"Diagnostic Delay and Characterization of the Clinical Prodrome in AL Amyloidosis among 1523 US Adults Diagnosed between 2001 and 2019","volume":"107","author":"Hester","year":"2021","journal-title":"Eur. J Haematol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"27","DOI":"10.14797\/mdcvj.1070","article-title":"Light Chain Amyloidosis: Epidemiology, Staging, and Prognostication","volume":"18","author":"Baker","year":"2022","journal-title":"Methodist DeBakey Cardiovasc. J."},{"key":"ref_21","first-page":"220","article-title":"Daratumumab in First-Line Treatment of Patients with Light Chain Amyloidosis and Mayo Stage IIIb Improves Treatment Response and Overall Survival","volume":"109","author":"Oubari","year":"2023","journal-title":"Haematologica"},{"key":"ref_22","first-page":"2355","article-title":"Efficacy and Safety of Daratumumab plus Bortezomib and Dexamethasone in Newly Diagnosed Mayo 2004 Stage IIIA or IIIB Light-Chain Amyloidosis: A Prospective Phase II Study","volume":"109","author":"Shen","year":"2024","journal-title":"Haematologica"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1182\/blood-2024-202932","article-title":"Efficacy and Safety of Daratumumab Monotherapy in Newly Diagnosed Patients with Stage 3B Light Chain Amyloidosis: A Phase 2 Study By the European Myeloma Network","volume":"144","author":"Kastritis","year":"2024","journal-title":"Blood"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1007\/s00277-023-05090-z","article-title":"Daratumumab plus Bortezomib, Cyclophosphamide, and Dexamethasone in Asian Patients with Newly Diagnosed AL Amyloidosis: Subgroup Analysis of ANDROMEDA","volume":"102","author":"Suzuki","year":"2023","journal-title":"Ann. Hematol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1111\/bjh.19766","article-title":"Factors Impeding Organ Recovery despite a Deep Haematological Response in Patients with Systemic AL Amyloidosis","volume":"205","author":"Staron","year":"2024","journal-title":"Br. J. Haematol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1111\/bjh.19810","article-title":"Piecing Together the Intricate Puzzle of Organ Recovery in AL Amyloidosis","volume":"205","author":"Nuvolone","year":"2024","journal-title":"Br. J. Haematol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1182\/blood-2024-202995","article-title":"Clinical Significance of Measurable Residual Disease (MRD) in Light-Chain (AL) Amyloidosis","volume":"144","author":"Lasa","year":"2024","journal-title":"Blood"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1182\/blood.2023022399","article-title":"Complete Responses in AL Amyloidosis Are Unequal: The Impact of Free Light Chain Mass Spectrometry in AL Amyloidosis","volume":"143","author":"Bomsztyk","year":"2024","journal-title":"Blood"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS8076","article-title":"Birtamimab in Patients with Mayo Stage IV AL Amyloidosis: Rationale for Confirmatory Affirm-AL Phase 3 Study","volume":"40","author":"Gertz","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1182\/blood-2023-186515","article-title":"Safety and Tolerability of Cael-101, an Anti-Amyloid Monoclonal Antibody, Combined with Anti-Plasma Cell Dyscrasia Therapy in Patients with Light-Chain Amyloidosis: 24-Month Results of a Phase 2 Study","volume":"142","author":"Valent","year":"2023","journal-title":"Blood"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1182\/blood-2024-205077","article-title":"Subcutaneous Daratumumab (DARA) + Bortezomib, Cyclophosphamide, and Dexamethasone (VCd) in Patients with Newly Diagnosed Light Chain (AL) Amyloidosis: Overall Survival and Final Major Organ Deterioration Progression-Free Survival Results from the Phase 3 Andromeda Study","volume":"144","author":"Kastritis","year":"2024","journal-title":"Blood"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1182\/blood.2021014613","article-title":"Daratumumab in AL Amyloidosis","volume":"140","author":"Wechalekar","year":"2022","journal-title":"Blood"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2157581","DOI":"10.1080\/16078454.2022.2157581","article-title":"Assessing the Prognostic Utility of Hematologic Response for Overall Survival in Patients with Newly Diagnosed AL Amyloidosis: Results of a Meta-Analysis","volume":"28","author":"Kastritis","year":"2023","journal-title":"Hematology"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1182\/blood.2024024623","article-title":"Patients with a Cardiac Complete Response in AL Amyloidosis Have Survival Rates Similar to Those of a Matched General Population","volume":"144","author":"Muchtar","year":"2024","journal-title":"Blood"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/9\/1440\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:21:25Z","timestamp":1760030485000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/9\/1440"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,25]]},"references-count":34,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,5]]}},"alternative-id":["cancers17091440"],"URL":"https:\/\/doi.org\/10.3390\/cancers17091440","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,25]]}}}